Evidence map›Paper›PMID 26539419›Full record

ArticleNephro-urology monthly2015

Adherence to Antihypertensives in Patients With Comorbid Condition.

Zahra Saadat, Farahnaz Nikdoust, Hossein Aerab-Sheibani, Mostafa Bahremand, Elham Shobeiri, Habibollah Saadat, Yashar Moharramzad, Donald E Morisky

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephro-urology monthly, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 6 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 6 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Zahra SaadatDepartment of Cardiology, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Farahnaz NikdoustDepartment of Cardiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
Hossein Aerab-SheibaniDepartment of Cardiology, Shahid Sadoughi University of Medical Sciences, Bafgh,Kermanshah, IR Iran.
Mostafa BahremandDepartment of Cardiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
Elham ShobeiriDepartment of Radiology, Kermanshah University of Medical Sciences,Kermanshah, IR Iran.
Habibollah SaadatDepartment of Cardiology, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Yashar MoharramzadDepartment of Cardiology, Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran.
Donald E MoriskyDepartment of Community Health Sciences, UCLA Fielding School of Public Health, Los Angeles, USA.
Shahid Beheshti University of Medical Sciences · IRKermanshah University of Medical Sciences · IRShahid Sadoughi University of Medical Sciences and Health Services · IRTehran University of Medical Sciences · IRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComorbidity has been noted as a potential barrier to proper adherence to antihypertensive medications.

objectivesWe decided to investigate whether comorbidity could significantly affect adherence of Iranian patients with hypertension to their medication regimen. PATIENTS AND

methodsTwo hundred and eighty consecutive hypertensive patients were interviewed in 4 cities of Iran. The 8-item Morisky medication adherence scale (MMAS-8) (validated in Persian) was used to assess medication adherence. This scale determines adherence by scores as lower than 6 (low adherence), 6 or 7 (moderate adherence), and 8 (high adherence). Comorbidity was considered as any concomitant medical condition, which necessitates the patient to take medicine for a minimum of 6 months prior to the interviews.

resultsThe most common comorbid conditions were ischemic heart disease (65 patients, 23.2%), diabetes mellitus (55 patients, 19.6%), and dyslipidemia (51 patients, 18.2%). Mean (± SD) MMAS-8 score in comorbid group was 5.68 (± 1.85) and in non-comorbid hypertensive patients, it was 5.83 (± 1.91) (P = 0.631). Mean (± SD) number of comorbidities was 1.53 (± 0.75) in low adherence group compared to 1.54 (± 0.77) in moderate/high adherers (P = 0.98). With increasing the number of comorbid diseases, the proportion of patients with high adherence decreased successively from 20% in those with no comorbid disease to 14.1% in those with one or two comorbid conditions, and finally 11.1% in those with 3 to 5 comorbid conditions.

conclusionsWith increasing the number of comorbid conditions, the proportion of patients with high adherence decreases. In our opinion, this finding is a useful clinical note for healthcare providers when managing patients with hypertension who have other medical problems at the same time.

Indexed as

Antihypertensive agentsComorbidityHypertensionIranMedication adherence

Identifiers

PMID26539419
PMCPMC4628207
OpenAlexW2116953835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.